Fluvoxamine Digoxin

GFJ has been shown to increase the exposure of carbamazepine (175), cisapride (176-179), fluvoxamine (184), losartan (188), methadone (189), scopolamine (191), and sertraline (192). However, only the interaction of GFJ with carbamazepine and cisapride seems to be clinically relevant. No alteration in exposure was observed for clozapine (180,181), heophylline (195), halo-peridol (196), and omeprazole (190). Reports of increased pharmacokinetic parameters of clozapine, theophylline, and haloperidol suggest that an interaction is unlikely to be clinically relevant. Contradicting results were reported for itraconazole (185-187), digoxin (75,183), and sildenafil (193,194). An increased effect on concomitant use of diclofenac and GFJ was observed in rats (182). Overall, the clinical relevance for this drug class appears to be low. 

Galantamine (Razadyne) [Cholinesterase Inhibitor] Uses Alzheimer Dz Action Acetylcholinesterase inhibitor Dose 4 mg PO bid, T to 8 mg bid after 4 wk may T to 12 mg bid in 4 wk Caution [B, ] T Effect w/ suc-cinylcholine, amiodarone, dildazem, verapamil, NSAIDs, digoxin X- effect w/ anticholinergics, T risk of death vs placebo Contra Severe renal/hepadc impair Disp Tabs, soln SE GI disturbances, wt loss, sleep disturbances, dizziness, HA Interactions T Effects W/ amitriptyline, cimeddine, erythromycin, fluoxetine, fluvoxamine, ketoconazole, paroxetine, quinidine EMS Use succinylcholine w/ caudon, may need a reduced dose monitor ECG for induced conduction abnormalities OD May cause cholinergic Sxs (SLUDGE), muscle weakness, resp depression, and Szs atropine may be used as antidote... 

Digitalis glycoside Neither citalopram nor fluvoxamine appear to interact with digoxin, but an isolated report describes increased serum digoxin levels attributed to the use of fluoxetine. 

Clinically important, potentially hazardous interactions with alcohol, aprepitant, clarithromycin, CNS depressants, delavirdine, digoxin, efavirenz, fluconazole, fluoxetine, fluvoxamine, grapefruit juice, indinavir, itraconazole, ivermectin, kava, ketoconazole, propoxyphene, ritonavir, saquinavir, St John s wort... 

Anagrelide should not be used with other phosphodiesterase III inhibitors (e.g. milrinone) because of the potential for increased inotropic effects. Inhibitors of CYP1A2 (e.g. fluvoxamine) are predicted to increase anagrelide levels. Some caution might be required with concurrent aspirin and other platelet inhibitors. Whether anagrelide inhibits theophylline metabolism to a clinically relevant extent is not known. No pharmacokinetic interaction occurs with digoxin or warfarin. 

Ochs HR, Greenblatt DJ, Verburg-Ochs B, Labedski L. Chronic treatment with fluvoxamine, clovoxamine and placebo interaction with digoxin and effects on sleep and alertness. J Clin Pharmacol(, 9S9)29,9 -95. 

---